Stuart Green

Creating the Leaders of Tomorrow: The Valuable 500 Reach Milestone for 'Generation Valuable' on International Day for Persons with Disabilities

Retrieved on: 
Thursday, December 1, 2022
Inauguration, WEF, Mental Disability Advocacy Center, London Stock Exchange, Workplace, ESG, Verizon Communications, Collective, Hotel manager, Caregiver, Stuart Green, Research, Creative Leadership, ISS, International, EY, AMS, P&G, Person, Macquarie Group, Mentorship, Business, Management, Mahindra, Nestlé

The programme modules include Creative Leadership, Leadership Identity, Strategic Thinking, Business for Good/ESG, and Disability Advocacy.

Key Points: 
  • The programme modules include Creative Leadership, Leadership Identity, Strategic Thinking, Business for Good/ESG, and Disability Advocacy.
  • LONDON, Dec. 1, 2022 /PRNewswire/ -- Celebrating International Day for Persons with Disabilities (IDPD) the Valuable 500 today announces reaching the goal of securing 75 mentees and mentors as the inaugural cohort for its innovative leadership 'Generation Valuable' programme from companies in every continent.
  • This follows the launch of the search for the leaders of tomorrow at WEF in May this year.
  • The programme will strengthen participants' personal leadership identities to cultivate environments that execute business strategies with an ESG and equity lens.

Veradigm Digital Health Media Becomes the First EHR Marketing Solution to Join the Point of Care Marketing Association

Retrieved on: 
Tuesday, November 22, 2022
Data Management, Practice Management, Technology, Health, Marketing, Communications, Health Technology, Apps, Applications, Software, Mobile, Wireless, Telemedicine, Virtual Medicine, Workflow, Point, Senior, POC, Connected, Stuart Green, Multimedia, MDRX, Caregiver, EHR, Growth, Education, HCPS, Management, Medicine, Allscripts

POCMA is excited to have Veradigm as a member and the first within the EHR landscape, said POCMA Executive Director, Nicole Divinagracia.

Key Points: 
  • POCMA is excited to have Veradigm as a member and the first within the EHR landscape, said POCMA Executive Director, Nicole Divinagracia.
  • Veradigms platform of reaching HCPs in their workflow makes them an excellent resource for the association and its members.
  • At Veradigm, we share in POCMAs goal of raising healthcare providers awareness through innovative point of care marketing channels, said Stuart Green, Senior Vice President & General Manager, Veradigm.
  • Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale.

COVID-19 Research Database Partners with the HHS Technology Group to Create a Scalable, Repeatable Model for Research

Retrieved on: 
Tuesday, June 7, 2022
Munich Re, Â, Entrepreneurship, Time, Policy, Integration, SAS, Publication, Technology, COVID-19, Research, Reagan-Udall Foundation, Privacy, HHS, Dassault Group, Change Healthcare, Software, CEO, Mathematica Policy Research, Partnership, List of life sciences, Solution, Silver, Government, Acorn, HCCI, VP, Kantō dialect, Influenza Research Database, Senior, Patient, Global Medical Device Nomenclature, Stanford University, General manager, Private sector, Friction, Population health, Health care, SVP, Disease, Stuart Green, GLOBE, SAN, Public health, Pharmaceutical industry, Medical imaging, Dietary supplement, Risk management, Management, Medicine, Medidata Solutions, Database

A partnership with the HHS Technology Group provides an incredible opportunity to continue accelerating research and bridging pandemic learnings into concrete positive changes across society.

Key Points: 
  • A partnership with the HHS Technology Group provides an incredible opportunity to continue accelerating research and bridging pandemic learnings into concrete positive changes across society.
  • Together with HHS Technology Group partners like Mathematica Policy Research who provide industry-leading data science and research expertise, the combined Research Database will serve to significantly accelerate the research communitys path to publication.
  • The COVID-19 Research Database has demonstrated that real-world data, made accessible through an open platform, can drive cutting-edge research and inform a better understanding of public health, said Brett Furst, President of HHS Technology Group.
  • The HHS Technology Group and the COVID-19 Research Database will work together to provide an open Research Database to an expanding community of researchers, public health leaders, government agencies, and policy makers.

Ventus Therapeutics Appoints Stuart Green, M.D., as Chief Medical Officer

Retrieved on: 
Monday, May 2, 2022
Health, Infectious Diseases, Clinical Trials, General Health, Pharmaceutical, Biotechnology, NLRP3, COVID-19, Duke University Hospital, University, Critical Care Medicine (journal), Duke, University of Texas Health Science Center at Houston, Pain scale, Merck, Stuart, Â, COPD, Asthma, Merck & Co., Inflammation, Therapy, Overactive bladder, Industry, Outline of health sciences, MD, Multimedia, Leadership, Neurology, Internal medicine, Duke University, CMO, LinkedIn, Stuart Green, Chronic cough, CEO, Protein, Resolve, Rheumatoid arthritis, Pharmaceutical industry, Fine chemical, Ventus, Chemistry

Ventus Therapeutics , Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational platform to identify and develop small molecule therapeutics across a broad range of diseases, announced today the appointment of Stuart Green, MD, as Chief Medical Officer.

Key Points: 
  • Ventus Therapeutics , Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational platform to identify and develop small molecule therapeutics across a broad range of diseases, announced today the appointment of Stuart Green, MD, as Chief Medical Officer.
  • We are excited to welcome Stuart to the Ventus team at this pivotal time in our evolution toward a clinical-stage company.
  • Dr. Green brings more than twenty years of experience in clinical development to Ventus.
  • Ventus Therapeutics is a biopharmaceutical company utilizing structural biology and computational tools to identify and develop small molecule therapeutics across a broad range of disease indications, with an initial focus on immunology, inflammation and neurology.